This section needs to be updated. Please help update this article to reflect recent events or newly available information.(December 2023)
A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval.[30]Efficacy is closely related to effectiveness, which is generally expected to slowly decrease over time.[31]
In December 2021, Novavax reported that its phase III trial showed the vaccine achieved its primary endpoint of preventing infection at least seven days after the second dose.[32] Overall efficacy against different SARS-CoV-2s was 90.4% and efficacy against moderate-to-severe disease was 100%.[33][32]
Trials were conducted before the emergence of the SARS-CoV-2 Omicron variant, which has sharply reduced the effectiveness of authorized vaccines in preventing infections.[34]
The most common side effects include fever, headache, nausea, muscle and joint pain, tenderness and pain at the injection site, tiredness, and feeling unwell.[4]
Additional possible side effects include anaphylaxis (severe allergic reaction), paresthesia (unusual feeling in the skin, such as tingling or a crawling sensation) and hypoesthesia (decreased feeling or sensitivity, especially in the skin), and pericarditis (inflammation of lining around the heart).[37] It has also been reported that myocarditis (inflammation of heart muscle cells) as reported incidence from receiving the NVX-CoV2373 vaccine.[38][39]
On 27 January 2023, Australia's Therapeutic Goods Administration indicated it will add tinnitus to its label.[40]
Handling and administration
The vaccine requires two doses[41] and is stable at 2 to 8 °C (36 to 46 °F) refrigerated temperatures.[42] The second dose can be administered three to eight weeks apart from the first dose.[43] The vaccine injection can be administered intramuscularly (ie. deltoid, upper thigh, or upper buttock). There are currently no drug interaction that may affect the vaccine's efficacy if administered with other vaccines at the same time.[43]
Pregnancy and breastfeeding
It is recommended that pregnant individuals, and those planning to get pregnant in the future, to get their COVID-19 vaccines updated . The vaccine is a recombinant protein, not a live virus, therefore it will not replicate and spread to the infant.[44] The patient should weigh the potential risks and complications if they decided to not get the virus due to insufficient data in pregnancy compared to being vaccinated for protection against the SARS-CoV-2 infection.
There are no studies conducted to trial the efficacy and safety of Novovax vaccine to patients who are breastfeeding. Since Novavax is not a live virus, it can be extrapolated that the vaccine will not replicate and concentrate in the breast milk.[44]
Technology
NVX-CoV2373 has been described as both a protein subunit vaccine[45][46] and a virus-like particle vaccine,[47][48] though the producers call it a "recombinant nanoparticle vaccine".[49] By engineering the nanoparticle to contain the virus spike protein as the antigen, it allows the immune cells to easily recognize the antigen as the target protein. [50]
The vaccine is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2spike protein.[51] The spike protein was modified by incorporating two proline amino acids in order to stabilize the pre-fusion form of the protein; this same 2P modification is being used in several other COVID‑19 vaccines.[52] The baculovirus is made to infect a culture of Sf9moth cells, which then create the spike protein and display it on their cell membranes. The spike proteins are harvested and assembled onto a synthetic lipid nanoparticle about 50 nanometers across, each displaying up to 14 spike proteins.[45][46][49]
Matrix-M adjuvant source is purified from Quillaja Saponaria Molina Tree. Matrix-M adjuvant is combined with the spike protein from the SARS-CoV-2 antigen to induce immune response in body upon vaccination. The adjuvant primarily enhances local antibodies and immunity at the local site of injection and draining lymph nodes. The adjuvant demonstrates its protection against the virus by inducing innate immune system rapidly. At the local site of injection, the adjuvant recruits antigen presenting cells and attracts more T cells, such as CD4+ and CD8+ T cells.[38] After entry of the vaccine nanoparticle containing the recombinant spike protein of the virus, it binds to ACE2 (angiotensin-converting enzyme 2) receptor to allow endocytosis and viral replication. However, upon endocytosis these viral particles are digested by lysosome and presented to MHC class molecules. This will lead to attracting T cells (CD4+ and CD8+).[53] This chemokine activity is further enhanced by the presence of the adjuvant component to enhance immune response from the viral particle. The cascade of immune activation leads to immediate immune response to target the virus as well as creating memory B cells specific to the antigen that the virus have.[38] These memory B cells enhances our immune response by faster immune cell recognition of these subsequent viral exposure to the same antigen compared to the initial exposure.[53]
Manufacturing
In February 2021, Novavax partnered with Takeda to manufacture the vaccine in Japan, where its COVID‑19 vaccine candidate is known as TAK-019.[54]
Novavax signed an agreement with Serum Institute of India for mass scale production for developing and low-income countries.[55] In 2020 it was reported, that the vaccine would be manufactured in Spain[56] and in November 2021 it was reported to be produced in Poland by the Mabion company.[57] As of 2021, antigens were made at Novavax's factory Novavax CZ in the Czech Republic;[58] Novavax CZ was also marketing authorisation holder of its EU authorization.[4]
In May 2021, Serum Institute of India said that it started the production of the Novavax COVID‑19 vaccine candidate branded as Covovax in India after receiving permission from the Indian government.[59]
History
In January 2020, Novavax announced development of a vaccine candidate, codenamed NVX-CoV2373, to establish immunity to SARS-CoV-2.[60] Novavax's work is in competition for vaccine development among dozens of other companies.[61]
In March 2020, Novavax announced a collaboration with Emergent BioSolutions for preclinical and early-stage human research on the vaccine candidate.[62] Under the partnership, Emergent BioSolutions was supposed to manufacture the vaccine at large scale at their Baltimore facility.[63] However, following production issues with the Johnson & Johnson and Oxford–AstraZeneca vaccines at its Baltimore plant and to decrease the burden on the plant, Novavax subsequently partnered with a different manufacturer in a new agreement overseen by the U.S. government.[64]
Trials have also taken place in the United Kingdom.[65][66] The first human safety studies of the candidate, codenamed NVX-CoV2373, started in May 2020 in Australia.[67][68]
In July 2020, the company announced it might receive US$1.6 billion from Operation Warp Speed to expedite development of its coronavirus vaccine candidate by 2021 – if clinical trials show the vaccine to be effective.[69][70] A spokesperson for Novavax stated that the $1.6 billion was coming from a "collaboration" between the Department of Health and Human Services and Department of Defense.[69][70]
Clinical trials
Phase I and II
In May 2020, Australia's first human trials of a candidate COVID‑19 vaccine, Novavax's NVX-CoV2373, began in Melbourne. It involved about 130 volunteers aged between 18-59.[71]
Phase III
In September 2020, Novavax started for a phase III trial with 15,000 in the UK.[72][73]
In December 2020 Novavax started the PREVENT-19 (NCT04611802) phase III trial in the US and Mexico, funded by NIAID and BARDA.[74][75]
In May 2021, Novavax initiated a pediatric expansion for the phase III clinical trial, with 3,000 adolescents 12–17 years of age in up to 75 sites in the United States.[76]
UK trial
In January 2021, Novavax reported that preliminary results from the United Kingdom trial showed that its vaccine candidate was more than 89% effective.[78][42]
The Thackray Museum of Medicine in Leeds hosted the largest cohort of volunteers. Trials of the Novavax vaccine were conducted on 5,000 people there during 2021.[79]
In June 2021, a primary Novavax-funded study found that the vaccine has an overall efficacy of 83.4% two weeks after the first dose and 89.7% one week after the second dose.[35] A post hoc analysis showed an efficacy of 86.3% against the B.1.1.7 (Alpha) variant and 96.4% against "non-B.1.1.7 strains", the majority of which were the "prototype strains" (original strain).[35][80]
South Africa trial
In January 2021, Novavax reported that interim results from a trial in South Africa showed a lower effectiveness rate against the Beta variant (lineage B.1.351), at around 50–60%.[41][81]
In a study reported in March and May 2021, the efficacy of the Novavax vaccine (NVX-CoV2373) was tested in a preliminary randomized, placebo-controlled study involving 2684 participants who were negative for COVID at baseline testing. The Beta variant was the predominant variant to occur, with post-hoc analysis indicating a cross-protective vaccine efficacy of Novavax against Beta of 51.0% for HIV-negative participants.[51][82][83]
US and Mexico trial
In June 2021, Novavax announced overall 90.4% efficacy in the phase III US & Mexico trial that involved nearly 30,000 people aged 18 years of age and older.[84] From the total 77 COVID-19 cases found in the trial participants, 14 occurred in the vaccine group, while 63 occurred in the placebo group.[85]
Administration
About 216,000 doses of the Novavax COVID-19 vaccine were administered in the EU/EEA from authorization to 26 June 2022.[37]
Legal status
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org.
In February 2021, the European Medicines Agency (EMA) started a rolling review of the Novavax COVID-19 vaccine (NVX‑CoV2373).[5] In November 2021, the EMA received application for conditional marketing authorization.[86] In December 2021, the European Commission granted a conditional marketing authorization across the EU, following a recommendation from the EMA, for it to be sold under the brand name Nuvaxovid.[87][4][88][89]
As of November 2021, it has been authorized for use in Indonesia,[90] the Philippines,[91] as of December in India,[92] as of January 2022 in South Korea,[93][94] Australia,[95][96] as of February 2022 in the United Kingdom,[97] Canada,[98] Taiwan,[99] and Singapore.[100][101] As of December 2021 it was validated by the World Health Organization.[102]
In June 2022, the FDA's advisory committee voted 21-0 with one abstention to recommend authorization of Novavax's vaccine for use in adults in the United States.[103][104] In July 2022, the FDA authorized NVX-CoV2373 for emergency use as a primary immunization (not booster) in adults.[105][24] making it the fourth COVID‑19 vaccine authorized in the US.[34] In July 2022, the US Centers for Disease Control and Prevention (CDC) recommended the Novavax COVID‑19 vaccine as a two-dose primary series for adults age 18 and older, thus endorsing the recommendation from the Advisory Committee on Immunization Practices (ACIP) regarding this vaccine.[106][107] In August 2022, the FDA granted Emergency Use Authorization for the Novavax COVID‑19 vaccine in people aged 12–17 years.[27] In August 2022, the CDC recommended the Novavax COVID‑19 vaccine for adolescents aged 12–17 years.[108]
In October 2023, the FDA amended the emergency use authorization of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the Novavax COVID-19 Vaccine, Adjuvanted (2023–2024 Formula) and removed the authorization for the Novavax COVID-19 Vaccine, Adjuvanted (Original monovalent).[109][110]
Notes
^ abcd28 September 2020 to January 2021, United Kingdom.[35] According to Nextstrain, during this period, the Alpha variant completely replaced the previously dominant lineage B.1.282 by the end of October.
^ abcdef"Nuvaxovid EPAR". European Medicines Agency (EMA). 17 December 2021. Archived from the original on 23 December 2021. Retrieved 23 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ ab"FDA Roundup: August 19, 2022". U.S. Food and Drug Administration (Press release). 19 August 2022. Archived from the original on 21 August 2022. Retrieved 20 August 2022.
^Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, et al. (12 September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". secondary. The Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. ISSN0140-6736. PMC7832749. PMID32861315. WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
^ ab"COVID-19 vaccines safety update"(PDF). European Medicines Agency. 3 August 2022. Archived(PDF) from the original on 3 August 2022. Retrieved 3 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ abWadman M, Jon C (28 January 2021). "Novavax vaccine delivers 89% efficacy against COVID-19 in UK – but is less potent in South Africa". Science. doi:10.1126/science.abg8101. S2CID234058820.
^ abcWadman M (28 December 2020). "Novavax launches pivotal U.S. trial of dark horse COVID-19 vaccine after manufacturing delays". Science. doi:10.1126/science.abg3441. S2CID234411557.
^Clinical trial number NCT04611802 for "A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2" at ClinicalTrials.gov
^Clinical trial number NCT04533399 for "A Phase 2A/B, Randomized,Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV" at ClinicalTrials.gov
^"Nuvaxovid". Union Register of medicinal products. European Commission. 6 July 2022. Archived from the original on 20 December 2021. Retrieved 23 December 2021.
Toyota AygoInformasiProdusenToyota Peugeot Citroën Automobile CzechMasa produksi2005-2022PerakitanKolin, Republik CekoBodi & rangkaKelasCity carMobil terkaitPeugeot 107Citroën C1Kia PicantoPenyalur dayaMesin1.0 L 1KR-FE I31.4 L DV4 HDi Mesin diesel I4DimensiJarak sumbu roda2.340 mm (92,1 in)Panjang3.405 mm (134,1 in)Lebar1.615 mm (63,6 in)Tinggi1.465 mm (57,7 in)Berat kosong890 kg (1.962 pon) Toyota Aygo merupakan salah satu produk mob…
The British AcademyTanggal pendirian1902StatusOrganisasi amalTipeAkademi nasionalKantor pusatLondon, InggrisJumlah anggota 1,000PresidenSir David CannadineSitus webthebritishacademy.ac.uk The British Academy adalah akademi nasional Britania Raya untuk bidang humaniora dan ilmu sosial. Didirikan pada tahun 1902 dan menerima Piagam Kerajaan pada tahun yang sama. Saat ini memiliki Fellowship lebih dari 1.000 sarjana terkemuka yang mencakup semua disiplin ilmu humaniora dan sosial serta badan pendan…
Gorō NonakaNama asli野中 五郎Lahir18 November 1910Yotsuya, Prefektur Tokyo, JepangMeninggal21 Maret 1945(1945-03-21) (umur 34)Prefektur Miyazaki, Tanjung Toi Misaki, JepangPengabdianAngkatan Laut Kekaisaran JepangLama dinas1934 - 1945Pangkat Kolonel Gorō Nonaka (野中五郎code: ja is deprecated , のなか ごろう) adalah seorang pilot Angkatan Laut Kekaisaran Jepang. Ia merupakan pilot veteran dalam membawa pesawat pengebom sedang dan pesawat pengebom torpedo. Ia digadang-ga…
Mountain in Alaska The MitreNorth aspect of The Mitre from Eklutna LakeHighest pointElevation6,651 ft (2,027 m)[1]Prominence1,751 ft (534 m)[1]Parent peakBenign Peak (7,235 ft)[2]Isolation2.37 mi (3.81 km)[2]Coordinates61°15′48″N 148°57′22″W / 61.26333°N 148.95611°W / 61.26333; -148.95611[1]GeographyThe MitreLocation of The Mitre in Alaska CountryUnited StatesStateAlaskaBoroughAnchorage…
2014 House elections in Texas See also: 2014 Texas elections 2014 United States House of Representatives elections in Texas ← 2012 November 4, 2014 2016 → All 36 Texas seats to the United States House of RepresentativesTurnout25% Majority party Minority party Third party Party Republican Democratic Libertarian Seats before 24 12 0 Seats won 25 11 0 Seat change 1 1 Popular vote 2,684,592 1,474,016 225,178 Percentage 60.28% 33.10% 5.06% Swing…
ConfidentSingel oleh Demi Lovatodari album ConfidentDirilis18 September 2015 (2015-09-18)GenrePower popelektropoppop rockDurasi3:25LabelHollywoodIslandRepublicSafehousePenciptaDemi LovatoIlya SalmanzadehMax MartinSavan KotechaProduserMax MartinIlyaKronologi singel Demi Lovato Cool for the Summer (2015) Confident (2015) Irresistible (2015) Video musikConfident di YouTube Confident adalah lagu oleh penyanyi asal Amerika Serikat, Demi Lovato. Lagu ini dirilis sebagai single kedua pada 18 Septe…
Ed, Edd n Eddy: The Mis-Edventures Publikasi 30 September 2005 Game Boy AdvanceGameCubePlayStation 2XboxWindows GenrePetualangan, PlatformKarakteristik teknisPlatformGame Boy Advance, Xbox, PlayStation 2, Windows dan Nintendo GameCube ModePermainan video pemain tunggal FormatCD-ROM Format kode Daftar 30 Informasi pengembangPengembangArtificial Mind and MovementPenyuntingMidway Games (en) KomponisPatric CairdPenerbitMidway GamesPenilaianESRB PEGI Informasi tambahanMobyGamesed-edd-n-eddy-the-mis-e…
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Florina Museum of Modern Art – news · newspapers · books · scholar · JSTOR (December 2020) (Learn how and when to remove this template message) Art museum in West Macedonia, GreeceFlorina Museum of Modern ArtEstablished1977LocationFlorina, West Macedonia, GreeceCo…
Litium diisopropilamida Nama Nama IUPAC Litium diisopropilamida Nama lain LDA Penanda Nomor CAS 4111-54-0 Model 3D (JSmol) Gambar interaktif 3DMet {{{3DMet}}} Nomor EC Nomor RTECS {{{value}}} CompTox Dashboard (EPA) DTXSID6063305 SMILES CC(C)[N-]C(C)C.[Li+] Sifat Rumus kimia C6H14LiN or LiN(C3H7)2 Massa molar 107,1233 g/mol Densitas 0,79 g/cm³ Kelarutan dalam air Bereaksi dengan air Kebasaan (pKb) -22 Bahaya Bahaya utama korosif Senyawa terkait Kecuali dinyatakan lain, data d…
Artikel ini memiliki beberapa masalah. Tolong bantu memperbaikinya atau diskusikan masalah-masalah ini di halaman pembicaraannya. (Pelajari bagaimana dan kapan saat yang tepat untuk menghapus templat pesan ini) Artikel ini perlu dikembangkan agar dapat memenuhi kriteria sebagai entri Wikipedia.Bantulah untuk mengembangkan artikel ini. Jika tidak dikembangkan, artikel ini akan dihapus. Artikel ini membutuhkan penyuntingan lebih lanjut mengenai tata bahasa, gaya penulisan, hubungan antarparagraf, …
Subfamily of viruses in the family Coronaviridae This article is about the group of viruses. For the disease involved in the COVID-19 pandemic, see COVID-19. For the virus that causes this disease, see SARS-CoV-2. Orthocoronavirinae Group member SARS-CoV-2 Illustration key: Blue: lipid bilayer envelope Light blue: spike (S) glycoprotein Red: envelope (E) proteins Green: membrane (M) proteins . Orange: glycan Virus classification (unrank…
Invasi GrenadaBagian dari Perang DinginPasukan payung Amerika Serikat menuju ke Grenada.Tanggal25 Oktober 1983 – 29 Oktober 1983LokasiGrenadaHasil Kemenangan Amerika SerikatRezim Militer runtuhPihak terlibat Amerika Serikat Antigua dan Barbuda Barbados Dominika Jamaika Saint Lucia Saint Vincent dan GrenadinesDidukung oleh : Oposisi Grenada Grenada KubaDidukung Oleh: Uni Soviet Korea UtaraTokoh dan pemimpin Ronald Reagan Norman Schwarzkopf Jr. Huds…
International certificate of vaccination Cover of the new International Certificate of Vaccination issued by the Bureau of Quarantine in the Philippines since 2021. The International Certificate of Vaccination or Prophylaxis (ICVP), also known as the Carte Jaune or Yellow Card, is an official vaccination report created by the World Health Organization (WHO).[1] As a travel document, it is a kind of medical passport that is recognised internationally and may be required for entry to certa…
Si ce bandeau n'est plus pertinent, retirez-le. Cliquez ici pour en savoir plus. Cet article ne cite pas suffisamment ses sources (mars 2009). Si vous disposez d'ouvrages ou d'articles de référence ou si vous connaissez des sites web de qualité traitant du thème abordé ici, merci de compléter l'article en donnant les références utiles à sa vérifiabilité et en les liant à la section « Notes et références ». En pratique : Quelles sources sont attendues ? Comment…
Scream VISutradara Matt Bettinelli-Olpin Tyler Gillett Produser William Sherak James Vanderbilt Paul Neinstein Ditulis oleh James Vanderbilt Guy Busick BerdasarkanKarakter-karakteroleh Kevin WilliamsonPemeran Courteney Cox Melissa Barrera Jenna Ortega Hayden Panettiere Jasmin Savoy Brown Mason Gooding Dermot Mulroney Jack Champion Liana Liberato Josh Segarra Devyn Nekoda Henry Czerny Tony Revolori Samara Weaving Skeet Ulrich Penata musik Brian Tyler Sven Faulconer SinematograferBrett Jutki…
Jean-Marie Pfaff Pfaff nel 2007 Nazionalità Belgio Altezza 180 cm Peso 78 kg Calcio Ruolo Allenatore (ex portiere) Termine carriera 1991 - giocatore Carriera Squadre di club1 1970-1982 Beveren276 (-?)1982-1988 Bayern Monaco156 (-165)1988-1989 Lierse23 (-?)1989-1990 Trabzonspor22 (-?) Nazionale 1976-1987 Belgio64 (-?) Carriera da allenatore 1998-1999 Ostenda Palmarès Europei di calcio Argento Italia 1980 1 I due numeri indicano le presenze e le reti segnate,…
Norse deity Heimdall and little Hnossa - how all things came to be (1920) by Willy Pogany. Hnoss (Old Norse: [ˈhnosː], jewel or treasure) is one of the daughters of Freyja and Óðr in Norse mythology.[1] Name The Old Norse term Hnoss has been translated in a variety of ways by scholars and folklorists. David Leeming and Christopher Fee in their joint book The Goddess: Myths of the Great Mother[2] claim that Hnoss' name was drawn from the word for gem, in which she is d…
Supreme Court of the United States38°53′26″N 77°00′16″W / 38.89056°N 77.00444°W / 38.89056; -77.00444EstablishedMarch 4, 1789; 235 years ago (1789-03-04)LocationWashington, D.C.Coordinates38°53′26″N 77°00′16″W / 38.89056°N 77.00444°W / 38.89056; -77.00444Composition methodPresidential nomination with Senate confirmationAuthorized byConstitution of the United States, Art. III, § 1Judge term lengthlife …
Cet article est une ébauche concernant l’automobile et le jeu vidéo. Vous pouvez partager vos connaissances en l’améliorant (comment ?) selon les recommandations des projets correspondants. Volant d'une voiture équipé d'un coussin gonflable de sécurité, airbag, et d'un avertisseur sonore mais sans bouton Volant d'un véhicule équipé d'un dispositif de coussin gonflable, d'un avertisseur sonore et de boutons de commandes/consignes audio et vitesse Dans une automobile, le volant …